Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, comments on the results from the Phase III MONALEESA-2 trial (NCT01958021) investigating first-line ribociclib plus letrozole versus placebo in postmenopausal women with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer. This study showed a significant benefit in overall survival (OS) for patients treated with combination therapy and could impact the current standard of care treatments. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

свернуть